Moving to human immunodeficiency virus type 1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity

Journal of Infectious Diseases

Volumn 187, Issue 2, 2003, Pages 226-242

  Russell, Nina D ^a,b   Hudgens, Michael G ^a   Ha, Richard ^a   Havenar Daughton, Colin ^a   McElrath, M Juliana ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SEROPREVALENCE; TREATMENT OUTCOME; VACCINATION;

AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HIV ANTIGENS; HIV-1; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; PEPTIDES; TIME FACTORS;

EID: 0037439309     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/367702     Document Type: Article

References (36)

1. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5.
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-10.
3. Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-74.
4. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
5. Rowland Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
6. Goh WC, Markee J, Akridge RE, et al. Protection against human immunodeficiency virus type I infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999;179:548-57.
7. Mazzoli S, Trabattoni D, Lo Caputo S, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997;3:1250-7.
8. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407-15.
9. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180:290-8.
10. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
11. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J infect Dis 2001;183:1343-52.
12. Ada GL, McElrath MJ. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. AIDS Res Hum Retroviruses 1997;13:205-10.
13. McElrath MJ, Siliciano RF, Weinhold KJ. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses 1997;13:211-6.
14. Pialoux G, Excler JL, Riviere Y, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses 1995;11:373-81.
15. Larsson M, Jin X, Ramratnam B, et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999;13:767-77.
16. + T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-35.
17. + memory T cells. J Exp Med 1997;186:859-65.
18. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISpot assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001;8:871-9.
19. Maeker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
20. Malhotra U, Holte S, Dutta S, et al. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001;107:505-17.
21. McElrath MJ, Corey L, Montefiori D, et al. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 2000;16:907-19.
22. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999;73:8179-84.
23. + T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol 2000;74:9144-51.
24. Agresti A. Categorical data analysis. Hoboken, NJ: John Wiley & Sons, 1990.
25. Lin L, Hedayat AS, Sinha B, Yang M. Statistical methods in assessing agreement: models, issues, and tools. J Am Stat Assoc 2002;97:257-70.
26. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute, 1996.
27. Johnson RP, Trocha A, Yang L, et al. HIV-1 Gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes: fine specificity of the Gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991;147:1512-21.
28. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-7.
29. Lieberman J, Fabry JA, Kuo MC, et al. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J Immunol 1992;148:2738-47.
30. Team AVEGP. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001;183:563-70.
31. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-61.
32. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92.
33. Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999;5:526-34.
34. Evans DT, O'Connor DH, Jing P, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 1999;5:1270-6.
35. Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-72.
36. + T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest 2000;106:1251-61.